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obert J. Myerburg, MD, Robert C. Hendel, MD
iami, Florida
rediction and prevention of sudden cardiac death (SCD) in
he individual patient remains a huge challenge for the
linician. Sudden cardiac death accounts for as many as 50%
f all cardiovascular deaths, and most SCDs occur either as
first cardiac event or as an unexpected incident among
atients in the large subgroup with recognized heart disease
hose profiles do not suggest a high risk for SCD (1). To
mpact upon the population burden of SCD, in parallel
ith benefitting the individual patient, it is necessary to
evelop risk-profiling strategies that distinguish small
ubsets at much higher risk within the general population
r among those with known disease currently classified at
ow risk.
See page 206
Two major risk-profiling strategies dominate the ap-
lication of our current knowledge on the subject. One
ocuses on high-risk subsets of patients with ischemic and
onischemic heart disease and some of the inherited
isorders associated with SCD risk, largely for the
urpose of identifying candidates for potentially lifesav-
ng implantable cardioverter defibrillator (ICD) therapy.
he other approach uses methodologies such as Framing-
am risk assessment and clinical markers of risk to
ncourage preventive and lifestyle-modification therapies
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, University of Miami Miller School of Medicine,
iami, Florida. Dr. Myerburg is funded in part by an American Heart Association
hair in Cardiovascular Research and by the Transatlantic Network on Sudden
ardiac Death, Fondation Leducq, Paris, France; has received consulting fees
uring the past 24 months from Boston Scientific Corporation, GlaxoSmithKline
harmaceuticals, and Sanofi-Aventis; and has received lecture fees from Boston
cientific Corporation, General Electric Company, and St. Jude Medical Corpo-
ation. Dr. Hendel receives honoraria from Astellas Pharma US; is a consultants
or PGx Health and GE Healthcare; and serves on the advisory board for
nitedHealthgroup.mong more general population sets. The efficiencies of
oth strategies have been disappointing. We have, in
egard to the high-risk subgroups used in the design of
he ICD trials, come to focus primarily on left ventricular
jection fractions (LVEFs)—usually dichotomized at
0% or 35%—as the major determinant of risk. The
ccuracy of the latter is limited by the absence of
tratifying at various levels of LVEF in the trials (2).
oreover, the methods used for determining LVEF also
ntroduce variability and inconsistency with regard to the
isk threshold, and variations within categories of LVEF
ight be modulated by clinical, anatomic, electrophysi-
logical, and autonomic factors that were not included in
he studies. Therefore, the power of individual risk-
rofiling on the basis of left ventricular function is
imited, especially when LVEFs are 30%. For the
eneral population, we have identified some reasonably
ood population stratifiers for the question of prevention
f SCD; but because the incidence is low within more
eneral populations, individual risk prediction remains
roblematic, despite the large cumulative numbers.
In recent years, the need to identify new risk-profiling
trategies and new technological approaches that are
ntended to yield better stratification have been discussed
n a number of publications, for both the high-risk
opulations and the more general subpopulations from
hich large numbers of SCDs emerge (3–6). Anatomic,
linical, and electrophysiological components have been
roposed or evaluated, but no 1 technique, or combina-
ion, seems to stand alone. The proposed targets include
he magnitude and pattern of myocardial scarring (e.g.,
VEF, heart failure, and contrast magnetic resonance
maging anatomy) and extent of coronary artery disease;
lectrophysiological and autonomic measures such as QT
nd heart rate variability, T-wave alternans, and biomar-
ers such as BNP; and comorbidities such as chronic
enal disease. One intriguing approach is the use of
eurohumoral imaging with iodine-123 metaiodobenzyl-
uanidine, which closely correlates with SCD, when
yocardial activity or washout rates of this tracer are
bnormal (5,6). Common to most of these discussions is
he notion that there is not likely to be a single marker or
that will achieve effective individual risk-profiling;
ather, more complex profiling strategies are needed.
ven the hope that a few genetic markers of risk,
tanding alone, will lead to better individual profiling is
iving way to the emerging recognition of the intricacies
f the genetic underpinnings of complex diseases due to
nteractions with clinical and environmental factors (7).
The problem is further complicated by the inaccuracy and
ariability related to the measurement of left ventricular
unction due to geometric assumptions and hemodynamic
onditions, including loading conditions. In addition,
VEF measurements at a point in time might not remain
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SPECT Imaging and SCD Prediction July 13, 2010:215–7nfarction patients. Furthermore, after acute coronary
yndromes, LVEF might either improve or worsen over
ime, and we have yet to define the implications of such
hanges in the context of the underlying substrate or their
ffect on risk prediction over time. Insight is needed into
he pathophysiological implications of dynamic changes
n risk-profiling as the markers change over time (8).
herefore, risk stratification becomes a dynamic process,
ften with relative subjectivity of many parameters, rather
han a static measure that provides consistent measures of
isk that can reliably be extrapolated for the prediction of
uture events.
In this issue of the Journal, Piccini et al. (9) present the
esults of a study examining risk stratification of SCD
isk in a cohort of 4,865 patients with angiographically
ocumented coronary artery disease and LVEF 35%,
ost of whom had normal global function (median value
1%). The study design was intended to determine
etrospectively whether SPECT myocardial perfusion
maging score, alone and in combination with other
easures, enabled identification of a subset within that
opulation who are at a high risk for SCD. Their primary
ethodological measure was summed stress score, a
ombined measure of fixed and reversible perfusion
efects, identified during stress imaging studies. The
uthors suggest that the magnitude of the perfusion
efects on SPECT stress testing identifies increasing risk
f SCD, particularly when combined with other markers
n a risk nomogram that included the SPECT score,
harleson score, and LVEF.
It is interesting to note that the summed difference score
as not predictive of SCD, suggesting that the presence of
t least some scar tissue is required to place the patient
ithin the high-risk group. This is supported by the
bservation within the paper (9) that the summed stress
core remains predictive of SCD even when adjusted for
evascularization. The pathophysiology underlying these
ndings is unknown, but scar tissue and/or transient
schemia might be involved in the initiation of cardiac arrest
10,11). Related to the summed score, it is unclear why the
hreshold value of 8 was selected; additional validation of
his cut-point is warranted either by a validation set of
ubjects or another trial, so as to demonstrate the ability to
pply this value in other cohorts.
The meritorious goal of risk-profiling within a large
ow-risk population, to identify a small high-risk subset,
eflects the need for new strategies for SCD prediction.
owever, the intriguing fact that the subset defined as
igh-risk (10% at 3 years) was concentrated in only
.5% of the total cohort is modulated by the observation
hat only 2 of 79 SCDs occurred in that subset, with the
emaining 77 SCDs occurring in the low-risk subgroup.
lthough the crude 3-year incidence of SCD in the
igh-risk group (2 of 26; 7.7%) was more than 4-fold
reater than the incidence in the low-risk group (77 of
,839; 1.6%), this risk-profiling strategy still limits ourbility to achieve high-risk resolution within a low-risk
ubset. Stated another way, only 2.5% of all SCDs were
dentified as high-risk by the SPECT nomogram. Most
CDs emerged from the subgroup with low summed
PECT scores. Whether the nomogram has more pre-
ictive power than evident in this study will require
rospective testing, likely in conjunction with additional
arkers.
A strategy employing SPECT imaging might also have
pplication to higher-risk post-myocardial infarction
opulations. Because ejection fraction alone does not
iscriminate ICD benefit as accurately as desired, espe-
ially among those with ejection fractions 30%, it
ould be intriguing to know whether this strategy would
e useful for discriminating risk in that important albeit
maller population. In contrast, for the estimated 30% to
0% of all SCDs that occur as first cardiac events, most
f whom will have coronary heart disease at postmortem
xamination, this strategy will not contribute to predic-
ion and prevention.
The current study should be viewed primarily as
ypothesis-generating, given its cross-sectional nature and
usceptibility to unintended bias. As the authors themselves
ecognize, these observations cannot be used for risk-
rofiling of the subset with coronary artery disease and
ormal ejection fractions at this time. Future prospective
tudies might identify a value that would be useful in large
linical trials. In the long run, the added costs of larger trials
ith additional stratifiers are justified because they may
ranslate into improved economy of therapeutics (8).
eprint requests and correspondence: Dr. Robert J. Myerburg,
ivision of Cardiology (D-39), University of Miami Miller School
f Medicine, P.O. Box 016960, Miami, Florida 33101. E-mail:
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